Dirk Thye, incoming CEO of Quince Therapeutics
Capping a turbulent saga around Alzheimer's drug, Cortexyme strikes a deal, brings in new management and changes name in search of new life
A failed attempt to bring forward an unorthodox approach to treating Alzheimer’s disease has culminated in the complete remake of Cortexyme.
The troubled public biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
